Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
The DOI matches its Crossref record; 253 of the 253 references it cites were found in a registry or an index.
Abstract
Highly potent, but poorly water-soluble, drug candidates are common outcomes of contemporary drug discovery programmes and present a number of challenges to drug development - most notably, the issue of reduced systemic exposure after oral administration. However, it is increasingly apparent that formulations containing natural and/or synthetic lipids present a viable means for enhancing the oral bioavailability of some poorly water-soluble, highly lipophilic drugs. This Review details the mechanisms by which lipids and lipidic excipients affect the oral absorption of lipophilic drugs and provides a perspective on the possible future applications of lipid-based delivery systems. Particular emphasis has been placed on the capacity of lipids to enhance drug solubilization in the intestinal milieu, recruit intestinal lymphatic drug transport (and thereby reduce first-pass drug metabolism) and alter enterocyte-based drug transport and disposition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conventional absorption and bioavailability assessments, and the body-weight regressions built upon them, implicitly assume the portal route and seldom quantify the lymphatic contribution, even though, for suitable compounds, it can represent a substantial fraction of systemic exposure [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“This route becomes quantitatively relevant only for compounds that combine high lipophilicity with appreciable long-chain triglyceride solubility, for which a log P greater than 5 and a lipid solubility above approximately 50 mg/g are commonly cited as approximate thresholds [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“Because lymphatic delivery reaches the systemic circulation while bypassing hepatic first-pass metabolism, it can materially increase the oral bioavailability of affected compounds and lower their apparent first-pass loss in a manner that a body-weight regression of systemic clearance or volume cannot anticipate [28,29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“For highly lipophilic drugs, a fraction of the absorbed dose can bypass the portal circulation entirely and reach the systemic circulation via the intestinal lymphatics, associated with triglyceride-rich lipoproteins (chylomicrons) assembled within the enterocyte [28,29].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“The extent of transport is highly sensitive to prandial state and to the type and quantity of co-administered lipid, which differ across preclinical study designs and between the fasted conditions typical of first-in-human protocols and the fed conditions under which lymphatic transport is greatest [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734 · cited 1×
“This is especially the case when potent, but highly lipophilic, drug candidates arise from complex chemical scaffolds and multiple high-throughput activity screen”
BackgroundNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., Kwiterovich, P., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,648
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 1×
“In addition to the potential effect of lipidic excipients (primarily surfactants) on P-gp-mediated efflux, Benet and co-workers have recently suggested that high-fat meals could inhibit P-g”
BackgroundSelf-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs
Neslihan Gursoy, R., & Benita, S. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.02.001 · Cited by 1,358
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J.-M. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,301
Cited by
Items 401–500 of 1,003
Ni, Y., Gu, Q., Li, J., & Fan, L. (2021) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2021.106738 · Cited by 76
Zhou, J., Zhou, M., Yang, F., Liu, C., Pan, R., Chang, Q., Liu, X., & Liao, Y. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5005838 · Cited by 76
McClements, D. J. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.837448 · Cited by 76
“These nutraceuticals are substances commonly found in foods that have health benefits over and above their normal roles as nutrients, such as w-3 fatty acids, conjugated linoleic acids, oil-soluble vitamins, carotenoids, flavonoids and phytosterols [2-5].”
BackgroundN’Goma, J. B., Williams, H. D., Sassene, P. J., Kleberg, K., Calderone, M., Jannin, V., Igonin, A., Partheil, A., Marchaud, D., Jule, E., et al. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1532-y · Cited by 76
“tion and oral bioavailability via several physiochemical and biological mechanisms, including avoidance of traditional drug dissolution processes, increased drug solubility in the intestine (6,8,9), increased intestinal permeability (10–12), decreased pre-systematic metabolism in the intestine (13) or enhancement of l…”
Self-citationYang, Y. R., Decker, E. A., Xiao, H., & McClements, D. J. (2014) · Food & Function · doi:10.1039/c4fo00725e · Cited by 76
Khan, J., Rades, T., & Boyd, B. J. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1829-5 · Cited by 76
Maurya, V. K., & Aggarwal, M. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.021 · Cited by 76
Liu, B., Liu, B., Wang, R., & Li, Y. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c06263 · Cited by 76
Formulation Strategies to Improve Oral Peptide Delivery
Maher, S., Ryan, B. K., Duffy, A. M., & Brayden, D. J. (2014) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.14.15 · Cited by 75
Dai, W., Pollock‐Dove, C., Dong, L. C., & Li, S. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.017 · Cited by 75
Leonavičiǖtė, G., Zupančič, O., Prüfert, F., Rohrer, J., & Bernkop‐Schnürch, A. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.04.044 · Cited by 75
Lin, Y., Wang, Y., Yang, X., Guo, J., & Wang, J. (2016) · LWT · doi:10.1016/j.lwt.2016.05.020 · Cited by 75
Akhtar, N., & Khan, R. A. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.08.005 · Cited by 76
Beg, S., Sharma, G., Thanki, K., Jain, S., Katare, O. P., & Singh, B. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.07.048 · Cited by 75
Čerpnjak, K., Pobirk, A. Z., Vrečer, F., & Gašperlin, M. (2014) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2014.971031 · Cited by 74
Beg, S., Katare, O. P., Saini, S., Garg, B., Khurana, R. K., & Singh, B. (2016) · Powder Technology · doi:10.1016/j.powtec.2016.02.023 · Cited by 74
Agrawal, S., Giri, T. K., Tripathi, D. K., Ajazuddin, M., & Alexander, A. (2012) · American Journal of Drug Discovery and Development · doi:10.3923/ajdd.2012.143.183 · Cited by 74
Mao, Y., Feng, S., Li, S., Zhao, Q., Di, D., Liu, Y., & Wang, S. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.012 · Cited by 74
Oral drug delivery of nanomedicine
Sahoo, D., Bandaru, R., Samal, S. K., Naik, R., Kumar, P., Kesharwani, P., & Dandela, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820466-5.00009-0 · Cited by 74
Ping, G., Wang, Y., Shen, L., Wang, Y., Hu, X., Chen, J., Hu, B., Cui, L., Meng, Q., & Li, C. (2017) · Chemical Communications · doi:10.1039/c7cc02799k · Cited by 73
Unnisa, A., Chettupalli, A. K., Hagbani, T. A., Khalid, M., Jandrajupalli, S. B., Chandolu, S., & Hussain, T. (2022) · Pharmaceuticals · doi:10.3390/ph15050568 · Cited by 73
“Increased insulin sensitivity could be one of the active mechanisms by which dapagliflozin-SLNs exert their anti-diabetic effects [14] The diabetic control group’s HbA1c level was slightly higher (p < 0.”
BackgroundSelf-assembled lipid–prodrug nanoparticles
Couvreur, P., Lepêtre‐Mouelhi, S., Garbayo, E., & Blanco‐Prieto, M. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00082-0 · Cited by 73
Nguyen, T., Hanley, T. L., Porter, C. J. H., Larson, I. C., & Boyd, B. J. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.62.07.0006 · Cited by 73
“Systems containing triglycerides and/or partially digested triglycerides as the lipid components (along with surfactants and cosolvents) are commonly employed, and characterisation of their in-vitro and in-vivo behaviour has received the most attention in the literature.([1,2]) However, aside from the potential for de…”
BackgroundSelf-citationWilliams, H. D., Speybroeck, M. V., Augustijns, P., & Porter, C. J. H. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23970 · Cited by 73
Self-citationHeshmati, N., Cheng, X., Eisenbrand, G., & Fricker, G. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23696 · Cited by 73
Engineered Nanoparticulate Drug Delivery Systems: The Next Frontier for Oral Administration?
Diab, R., Jaafar‐Maalej, C., Fessi, H., & Maincent, P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9377-y · Cited by 73
“Interestingly, the resultant mixed micelles can behave as excellent carriers for poorly water-soluble drug molecules and one of the most important mesophases before absorption (72).”
BackgroundImpact of salt and lipid type on in vitro digestion of emulsified lipids
Hur, S. J., Joo, S.-T., Lim, B. O., Decker, E. A., & McClements, J. D. (2010) · Food Chemistry · doi:10.1016/j.foodchem.2010.12.003 · Cited by 73
Shah, M. K., Madan, P. L., & Lin, S. (2013) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2013.795169 · Cited by 73
Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy
Bala, V., Rao, S., Li, P., Wang, S., & Prestidge, C. A. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00785 · Cited by 73
Zhang, R., & McClements, D. J. (2016) · Food Structure · doi:10.1016/j.foostr.2016.07.006 · Cited by 73
Lipids in the Stomach – Implications for the Evaluation of Food Effects on Oral Drug Absorption
Koziolek, M., Carrière, F., & Porter, C. J. H. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2289-x · Cited by 73
“reader is referred to the following reviews (6,120).”
BackgroundMethodSelf-citationGasa-Falcon, A., Odriozola‐Serrano, I., Oms‐Oliu, G., & Martín‐Belloso, O. (2019) · Food & Function · doi:10.1039/c8fo02069h · Cited by 73
Yao, M., Li, Z., McClements, D. J., Tang, Z., & Xiao, H. (2020) · Food Chemistry · doi:10.1016/j.foodchem.2020.126229 · Cited by 73
Current understandings and clinical translation of nanomedicines for breast cancer therapy
Jiang, Y., Jiang, Z., Wang, M., & Ma, L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114034 · Cited by 72
Development of oil-based gels as versatile drug delivery systems for pediatric applications
Kirtane, A. R., Karavasili, C., Wahane, A. V., Freitas, D., Booz, K., Le, D. T. H., Hua, T., Scala, S., Lopes, A., Hess, K., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm8478 · Cited by 72
“Last, much is known about the digestion of oily excipients and their influence on drug absorption ( 50 ).”
Holm, R., Kuentz, M., Ilie, A.-R., & Griffin, B. T. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106556 · Cited by 74
Burra, M., Jukanti, R., Janga, K. Y., Sunkavalli, S., Velpula, A., Ampati, S., & Jayaveera, K. N. (2012) · Advanced Powder Technology · doi:10.1016/j.apt.2012.09.002 · Cited by 72
Su, L., Yang, Y., Huang, Dou, D., & Zhai (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s47510 · Cited by 72
“22,23 26 The relative bioavailability of silymarin in a SMEDDS increased dramatically by 1.88-fold and 48.82-fold compared with silymarin in polyethylene glycol 400 solution and suspension, respectively.”
InfluentialThe comparison of different daidzein-PLGA nanoparticles in increasing its oral bioavailability
Shen, Q., Ma, Zhao, Y., & Shen, Q. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s27641 · Cited by 72
“45 48 Cyclodextrin has been proven as a drug absorption enhancer as well.”
Selection of oral bioavailability enhancing formulations during drug discovery
Zheng, W., Jain, A., Papoutsakis, D., Dannenfelser, R., Panicucci, R., & Garad, S. (2011) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2011.602406 · Cited by 72
Kong, F., Zhang, H., Qu, X., Zhang, X., Chen, D., Ding, R., Mäkilä, E. M., Salonen, J., Santos, H. A., & Hai, M. (2016) · Advanced Materials · doi:10.1002/adma.201602763 · Cited by 72
Alskär, L. C., Keemink, J., Johannesson, J., Porter, C. J. H., & Bergström, C. A. S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00699 · Cited by 73
Self-citationPalucki, M., Higgins, J. D., Kwong, E. C., & Templeton, A. C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1002638 · Cited by 72
Nguyen, T., Hanley, T. L., Porter, C. J. H., Larson, I. C., & Boyd, B. J. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.62.07.0005 · Cited by 72
“Co-administration of poorly water soluble drugs with lipids often improves the oral bioavailability of the drug by a number of mechanisms, including maintaining the drug in a persistent solubilised state, delaying gastric emptying, promoting lymphatic transport pathways (thereby bypassing first-pass hepatic metabolism…”
BackgroundSelf-citationNutraceutical Concepts and Dextrin-Based Delivery Systems
Hoti, G., Matencio, A., Pedrazzo, A. R., Cecone, C., Appleton, S. L., Monfared, Y. K., Caldera, F., & Trotta, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084102 · Cited by 71
Zhang, Z., Huang, J., Jiang, S., Liu, Z., Gu, W., Yu, H., & Li, Y. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.021 · Cited by 71
Downscaling Drug Nanosuspension Production: Processing Aspects and Physicochemical Characterization
Eerdenbrugh, B. V., Stuyven, B., Froyen, L., Humbeeck, J. V., Martens, J. A., Augustijns, P., & den Mooter, G. V. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-008-9170-5 · Cited by 71
“Examples of such formulation strategies are complexation (2), solid dispersions (3), lipid formulations ( 4 ), and particle size reduction (5).”
BackgroundBiomimetic thiamine- and niacin-decorated liposomes for enhanced oral delivery of insulin
He, H., Lü, Y., Qi, J., Zhao, W., Dong, X., & Wu, W. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.11.007 · Cited by 71
Pentafragka, C., Symillides, M., McAllister, M. S., Dressman, J., Vertzoni, M., & Reppas, C. I. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12999 · Cited by 71
“For BCS class IV drugs, the impact of extensive luminal solubilization in the fed state is even less straightforward as in this case transport through the mucosa may also be influenced by changes in the membrane fluidization (which may be induced by the interaction with surfactants) or the activity of membrane transpo…”
BackgroundLipid-Based Nanosystem As Intelligent Carriers for Versatile Drug Delivery Applications
Harshita, Barkat, M. A., Das, S. S., Pottoo, F. H., Beg, S., & Rahman, Z. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200206094529 · Cited by 71
Integrated in silico formulation design of self-emulsifying drug delivery systems
Gao, H., Jia, H., Dong, J. N., Yang, X., Li, H., & Ouyang, D. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.04.017 · Cited by 70
Crum, M., Trevaskis, N. L., Williams, H. D., Pouton, C. W., & Porter, C. J. H. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1843-7 · Cited by 70
“Lipid-based formulations (LBFs) provide one such approach to overcoming absorption limitations for poorly water-soluble drugs (PWSDs) (4, 5).”
BackgroundSelf-citationCui, Y., Shan, W., Zhou, R., Liu, M., Wu, L., Guo, Q., Zheng, Y., Wu, J., & Huang, Y. (2017) · Nanoscale · doi:10.1039/c7nr06063g · Cited by 70
Masjedi, M., Azadi, A., Heidari, R., & Mohammadi‐Samani, S. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13316 · Cited by 69
Zheng, G., Zhang, B., Yu, H., Song, Z., Xu, X., Zheng, Z., Zhao, K., Zhao, J. H., & Zhao, Y. (2025) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-025-01292-3 · Cited by 70
Strategies for the design of orally bioavailable antileishmanial treatments
Pham, T.-M.-H., Loiseau, P. M., & BARRATT, G. M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.07.035 · Cited by 69
Li, P., Hynes, S. R., Haefele, T., Pudipeddi, M., Royce, A. E., & Serajuddin, A. T. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21547 · Cited by 69
Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement
Rezhdo, O., Speciner, L., & Carrier, R. L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.050 · Cited by 71
“Size and structure of colloids are important to study as they directly affect oral drug partitioning and capacity to serve as a vehicle for drug transport along the GI tract [2].”
BackgroundSahbaz, Y., Nguyen, T., Ford, L., McEvoy, C. L., Williams, H. D., Scammells, P. J., & Porter, C. J. H. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00442 · Cited by 69
Self-citationEncapsulated phenolic compounds: clinical efficacy of a novel delivery method
Özkan, G., Ceyhan, T., Çatalkaya, G., Rajan, L., Ullah, H., Daglia, M., & Çapanoğlu, E. (2024) · Phytochemistry Reviews · doi:10.1007/s11101-023-09909-5 · Cited by 68
“…their physiochemical properties (i.e., limited liberation from the food matrix (Moelants et al. 2012), poor solubility in gastrointestinal fluids (Porter et al. 2007; Pouton and Porter 2008), low permeability across the epithelial cells (Martinez and Amidon 2002; Actis-Goretta et al. 2013),…”
Stillhart, C., Dürr, D., & Kuentz, M. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23892 · Cited by 68
Application of Lipid-Based Formulations in Drug Discovery
Chen, X.-Q., Gudmundsson, O. S., & Hageman, M. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3006433 · Cited by 62
Riethorst, D., Baatsen, P., Remijn, C., Mitra, A., Tack, J. F., Brouwers, J., & Augustijns, P. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00496 · Cited by 68
Kumar, R., Sirvi, A., Kaur, S., Samal, S. K., Roy, S., & Sangamwar, A. T. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105466 · Cited by 68
Hu, M., Li, Y., Decker, E. A., Xiao, H., & McClements, D. J. (2010) · Food Biophysics · doi:10.1007/s11483-010-9173-0 · Cited by 67
Ravi, P. R., Vats, R., Dalal, V., & Murthy, A. N. (2014) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12217 · Cited by 67
“It has been reported that lipid nanoparticles reach lymphatic system either by direct endocytosis/transcytosis uptake by membranous epithelial cells (M-cells) covering Payer’s patches in intestine or by conversion into triglyceride-rich lipoprotein particles called chylomicrons, which are secreted into intestinal lymp…”
BackgroundGraf, B. A., Duchateau, G. S. M. J. E., Patterson, A. B., Mitchell, E. S., van Bruggen, P., Koek, J. H., Melville, S., & Verkade, H. J. (2010) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2010.05.004 · Cited by 67
DHA rich algae oil delivered by O/W or gelled emulsions: strategies to increase its bioaccessibility
Gayoso, L., Ansorena, D., & Astiasarán, I. (2018) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.9420 · Cited by 67
Jo, M., Ban, C., Goh, K. K. T., & Choi, Y. J. (2019) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2019.04.010 · Cited by 67
Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms
Williams, H. D., Ford, L., Igonin, A., Shan, Z., Botti, P., Morgen, M. M., Hu, G., Pouton, C. W., Scammells, P. J., Porter, C. J. H., et al. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.008 · Cited by 67
Self-citationMixed lipid phase SMEDDS as an innovative approach to enhance resveratrol solubility
Seljak, K. B., Pobirk, A. Z., & Gašperlin, M. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.749888 · Cited by 66
Anaphylactic Reactions to Oligosaccharides in Red Meat: a Syndrome in Evolution
Saleh, H., Embry, S., Nauli, A. M., Atyia, S., & Krishnaswamy, G. A. (2012) · Clinical and Molecular Allergy · doi:10.1186/1476-7961-10-5 · Cited by 66
“On the other hand, insoluble dietary nutrients including long-chain triglycerides, cholesterol, and lipid-soluble vitamins are packaged by the small intestine into VLDLs and chylomicrons for transport through the lymphatic circulation [102].”
BackgroundKim, B., Cho, A.-R., & Park, D.-J. (2016) · Food Chemistry · doi:10.1016/j.foodchem.2016.03.052 · Cited by 66
Deng, X., Zhang, N., & Tang, C. (2016) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.8033 · Cited by 66
Maurya, V. K., & Aggarwal, M. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105429 · Cited by 66
Garai, S., Kulkarni, P. M., Schaffer, P. C., Leo, L. M., Brandt, A. L., Zagzoog, A., Black, T., Lin, X., Hurst, D. P., Janero, D. R., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01142 · Cited by 66
Kalhapure, R. S., & Akamanchi, K. G. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.01.004 · Cited by 66
Formation of bicalutamide nanodispersion for dissolution rate enhancement
Li, C., Li, C., Le, Y., & Chen, J. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.11.015 · Cited by 66
Application of Lipid Nanocarriers for the Food Industry
Rafiee, Z., & Jafari, S. M. (2018) · Reference series in phytochemistry · doi:10.1007/978-3-319-54528-8_93-1 · Cited by 65
Gangemi, C. M. A., Pappalardo, A., & Sfrazzetto, G. T. (2015) · RSC Advances · doi:10.1039/c5ra09364c · Cited by 65
Williams, H. D., Ford, L., Lim, S. F., Han, S., Baumann, J. M., Sullivan, H., Vodak, D. T., Igonin, A., Benameur, H., Pouton, C. W., et al. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.05.019 · Cited by 65
Self-citationTonda‐Turo, C., Origlia, N., Mattu, C., Accorroni, A., & Chiono, V. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180221125759 · Cited by 65
Lv, S., Gu, J., Zhang, R., Zhang, Y., Tan, H., & McClements, D. J. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b03077 · Cited by 65
Holm, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.009 · Cited by 65
Zhou, X. W., Ling, K., Liu, M., Zhang, X., Ding, J., Dong, Y., Liang, Z., Li, J., & Zhang, J. (2019) · Theranostics · doi:10.7150/thno.35353 · Cited by 66
“On the other hand, oral drug delivery is preferred for the treatment of different diseases, due to its multiple advantages such as convenience, relatively good safety profile, high patient compliance and adherence, and desirable cost-effectiveness [45, 46].”
BackgroundSchultz, H. B., Meola, T. R., Thomas, N., & Prestidge, C. A. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119069 · Cited by 66
Wang, Y., Gou, K., Guo, X., Ke, J., Li, S., & Li, H. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.01.005 · Cited by 65
Wu, B., Liu, H., Chen, G., Zhang, Y., & Ma, Z. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s73340 · Cited by 65
“13 Generally, lipid carriers can improve the oral absorption of drug through three mechanisms: solubilize drug into the intestinal milieu; facilitate drug transport by interacting with the enterocytes; and reduce the first-pass effect by altering transport pathway (portal vein versus lymphatic…”
Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport
Elz, A. S., Trevaskis, N. L., Porter, C. J. H., Bowen, J. M., & Prestidge, C. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.003 · Cited by 64
Self-citationYang, J., Zhou, Y., & Chen, L. (2013) · Food & Function · doi:10.1039/c3fo60351b · Cited by 64
Thi, T. D., Speybroeck, M. V., Mols, R., Annaert, P., Martens, J. A., Humbeeck, J. V., Vermant, J., Augustijns, P., & den Mooter, G. V. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.009 · Cited by 65
“However, the latter is ikely to enhance the lymphatic transport of a lipophilic drug subtance, which prevents first-pass metabolism (Caliph et al., 2000; orter et al., 2007).”
BackgroundRezhdo, O., Maio, S. D., Le, P., Littrell, K. C., Carrier, R. L., & Chen, S. H. (2017) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2017.03.109 · Cited by 64
“As a result, understanding the changes in their physicochemical properties during lipid digestion is critical in predicting and exploiting their effects in compound delivery in the GI tract [3].”
BackgroundMethodVitamin A fortification: Recent advances in encapsulation technologies
Maurya, V. K., Shakya, A., Bashir, K., Kushwaha, S. C., & McClements, D. J. (2022) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12941 · Cited by 63
Phospholipid-based solid drug formulations for oral bioavailability enhancement: A meta-analysis
Fong, S. Y. K., Brandl, M., & Bauer‐Brandl, A. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.08.005 · Cited by 63
“It has been discussed that PLs may inhibit the exsorptive transport by P-gp (Porter et al., 2007; Simon and Schubert, 2012).”
BackgroundInfluentialLi, Y., Kim, J., Park, Y., & McClements, D. J. (2012) · Food & Function · doi:10.1039/c2fo10273k · Cited by 63
Garg, B., Katare, O. P., Beg, S., Lohan, S., & Singh, B. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.02.012 · Cited by 63
Ting, Y., Jiang, Y., Lan, Y., Xia, C., Lin, Z., Rogers, M. A., & Huang, Q. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5007322 · Cited by 60
Bu, P., Narayanan, S., Dalrymple, D. M., Cheng, X., & Serajuddin, A. T. M. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.06.011 · Cited by 63
Lipid-Based Nanocarriers for the Oral Administration of Biopharmaceutics
Karamanidou, T., Bourganis, V., Kammona, O., & Kiparissides, C. A. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0265 · Cited by 64
Maurya, S. D., Arya, R. K. K., Rajpal, G., & Dhakar, R. C. (2017) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v7i3.1453 · Cited by 63
Metadata
- Authors
- Porter, C. J. H., Trevaskis, N. L., & Charman, W. N.
- Affiliations
- Monash University (AU)
- Corresponding author
- Porter, Christopher J. H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-03
- Volume
- 6
- Issue
- 3
- Pages
- 231-248
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2069235788
- Cited by
- 1,824
- References
- 253
- Citations by year
- 2026: 88 · 2025: 87 · 2024: 67 · 2023: 89 · 2022: 119 · 2021: 108 · 2020: 140 · 2019: 101 · 2018: 117 · 2017: 121 · 2016: 125 · 2015: 119 · 2014: 120 · 2013: 128 · 2012: 94
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- lipid-based drug delivery, oral bioavailability, lipophilic drugs, poorly water-soluble drugs, lipid excipients, first-pass metabolism, lipid-based formulations
- MeSH terms
- Administration, Oral, Animals, Pharmaceutical Preparations, Excipients, Humans, Intestinal Absorption, Lipids, Drug Design, Drug Delivery Systems, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.